An automated 24-hour CAR-T manufacturing process

Cell & Gene Therapy Insights 2024; 10(4), 441–452

DOI: 10.18609/cgti.2024.058

Published: 8 May
Innovator Insight
Mina Ahmadi

As the cell therapy field progresses, manufacturing challenges like patient safety, cost, automation, closed operation, and scalability must be addressed with improved capabilities and workflows. Leveraging new cell therapy technologies and tools to develop innovative end-to-end workflows can enable more cost-effective cell therapy processes and workflows. This article presents an automated and shortened lentiviral-based CAR-T workflow using the GibcoTM  CTSTM  Detachable DynabeadsTM  CD3/CD28 magnetic beads, GibcoTM CTSTM Detachable DynabeadsTM  Release Buffer, and GibcoTM  CTSTM   DynaCellectTM  Magnetic Separation System.